Clinical Trials Logo
  1. Home
  2. Cutaneous T-Cell Lymphoma
  3. NCT00779896

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Cutaneous T-Cell Lymphoma Clinical Trial

Official title:
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Clinical Trial Summary

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00779896
Study type Interventional
Source McGill University
Contact David Roberge
Phone 514-934-1934
Email david.roberge@muhc.mcgill.ca
Status Recruiting
Phase Phase 1/Phase 2
Start date October 2008
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Completed NCT00744991 - A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma Phase 2
Completed NCT00099593 - Immunization Against Tumor Cells in Sezary Syndrome Phase 2
Completed NCT02593045 - Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Phase 1
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Completed NCT01728805 - Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Phase 3
Withdrawn NCT00969085 - Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Phase 2
Completed NCT00412997 - LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma Phase 1
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Recruiting NCT04296786 - Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study Phase 2
Recruiting NCT06285370 - A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy Phase 4
Completed NCT00071084 - Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Phase 2
Completed NCT00896493 - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Phase 2
Terminated NCT00699296 - Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma Phase 2
Completed NCT02676778 - Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Phase 2
Terminated NCT02061449 - Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Phase 1
Completed NCT01134341 - Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05296304 - A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides Phase 1